{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Skin+Cancer&page=2",
    "query": {
      "condition": "Metastatic Skin Cancer",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Skin+Cancer&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-25T19:01:08.046Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07205822",
      "title": "A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Dato-DXd",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2025-10-30",
      "completion_date": "2028-02-02",
      "has_results": false,
      "last_update_posted_date": "2026-05-12",
      "last_synced_at": "2026-06-25T19:01:08.046Z",
      "location_count": 6,
      "location_summary": "Largo, Florida • Fort Wayne, Indiana • Omaha, Nebraska + 3 more",
      "locations": [
        {
          "city": "Largo",
          "state": "Florida"
        },
        {
          "city": "Fort Wayne",
          "state": "Indiana"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07205822"
    },
    {
      "nct_id": "NCT00120939",
      "title": "Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Neoplasms",
        "Ovarian Neoplasms",
        "Prostatic Neoplasms",
        "Lung Neoplasms",
        "Gastrointestinal Neoplasms"
      ],
      "interventions": [
        {
          "name": "Motexafin Gadolinium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pharmacyclics LLC.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2009-04-03",
      "last_synced_at": "2026-06-25T19:01:08.046Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00120939"
    },
    {
      "nct_id": "NCT05104866",
      "title": "A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Dato-DXd",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Eribulin",
          "type": "DRUG"
        },
        {
          "name": "Vinorelbine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 732,
      "start_date": "2021-10-18",
      "completion_date": "2026-07-31",
      "has_results": true,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-06-25T19:01:08.046Z",
      "location_count": 14,
      "location_summary": "Duarte, California • Los Angeles, California • Palo Alto, California + 10 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05104866"
    },
    {
      "nct_id": "NCT05277051",
      "title": "First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "Remzistotug",
          "type": "DRUG"
        },
        {
          "name": "Dostarlimab",
          "type": "DRUG"
        },
        {
          "name": "Belrestotug",
          "type": "DRUG"
        },
        {
          "name": "Nelistotug",
          "type": "DRUG"
        },
        {
          "name": "GSK5764227",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 152,
      "start_date": "2022-03-22",
      "completion_date": "2027-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-25",
      "last_synced_at": "2026-06-25T19:01:08.046Z",
      "location_count": 7,
      "location_summary": "San Francisco, California • Charlotte, North Carolina • Oklahoma City, Oklahoma + 4 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05277051"
    },
    {
      "nct_id": "NCT00708019",
      "title": "Improving Cancer Pain Management Through Self-Care",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cancer",
        "Pain"
      ],
      "interventions": [
        {
          "name": "PRO-SELF PLUS Pain Management Program",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 185,
      "start_date": "2007-12",
      "completion_date": "2013-06",
      "has_results": true,
      "last_update_posted_date": "2016-05-05",
      "last_synced_at": "2026-06-25T19:01:08.046Z",
      "location_count": 2,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00708019"
    },
    {
      "nct_id": "NCT04563507",
      "title": "Combined Immunotherapies in Metastatic ER+ Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions)",
          "type": "RADIATION"
        },
        {
          "name": "Letrozole 2.5Mg Tab",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib 125mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 90 Years · Female only"
      },
      "enrollment_count": 102,
      "start_date": "2020-11-12",
      "completion_date": "2028-10-31",
      "has_results": false,
      "last_update_posted_date": "2025-12-15",
      "last_synced_at": "2026-06-25T19:01:08.046Z",
      "location_count": 3,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04563507"
    },
    {
      "nct_id": "NCT00030537",
      "title": "Erlotinib in Treating Patients With Locally Advanced or Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "erlotinib hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2001-11",
      "completion_date": "2003-03",
      "has_results": false,
      "last_update_posted_date": "2013-06-19",
      "last_synced_at": "2026-06-25T19:01:08.046Z",
      "location_count": 2,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00030537"
    },
    {
      "nct_id": "NCT01280565",
      "title": "Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Melanoma"
      ],
      "interventions": [
        {
          "name": "Masitinib",
          "type": "DRUG"
        },
        {
          "name": "Dacarbazine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AB Science",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 134,
      "start_date": "2011-01",
      "completion_date": "2019-08",
      "has_results": false,
      "last_update_posted_date": "2020-11-05",
      "last_synced_at": "2026-06-25T19:01:08.046Z",
      "location_count": 1,
      "location_summary": "Charlotte, North Carolina",
      "locations": [
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01280565"
    },
    {
      "nct_id": "NCT02259231",
      "title": "RTA 408 Capsules in Patients With Melanoma - REVEAL",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Melanoma",
        "Unresectable (Stage III) Melanoma",
        "Metastatic (Stage IV) Melanoma"
      ],
      "interventions": [
        {
          "name": "Omaveloxolone Capsules (2.5 mg/capsule)",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab (3 mg/kg)",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab (240 mg)",
          "type": "DRUG"
        },
        {
          "name": "Omaveloxolone Capsules (10 mg/capsule)",
          "type": "DRUG"
        },
        {
          "name": "Omaveloxolone Capsules (50 mg/capsule)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2014-10-31",
      "completion_date": "2018-07-23",
      "has_results": true,
      "last_update_posted_date": "2025-06-04",
      "last_synced_at": "2026-06-25T19:01:08.046Z",
      "location_count": 10,
      "location_summary": "Mobile, Alabama • Fayetteville, Arkansas • Aurora, Colorado + 7 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02259231"
    },
    {
      "nct_id": "NCT05570253",
      "title": "A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Metastatic Triple-Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Eribulin",
          "type": "DRUG"
        },
        {
          "name": "SDX-7320",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2022-10-03",
      "completion_date": "2027-10",
      "has_results": false,
      "last_update_posted_date": "2026-04-27",
      "last_synced_at": "2026-06-25T19:01:08.046Z",
      "location_count": 10,
      "location_summary": "Miami, Florida • Atlanta, Georgia • Basking Ridge, New Jersey + 7 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05570253"
    }
  ]
}